Known hypersensitivity to any component of bevacizumab
Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulation
Known hypersensitivity to any component of the formulation or substituted benzimidazoles
Patients with known hypersensitivity to any component of the chemotherapy regimen will not be eligible
Known hypersensitivity to any component of bevacizumab
Known prior severe hypersensitivity to the investigational products or any component in their formulations,
Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations
Known hypersensitivity or allergy to murine products or any component of the obinutuzumab, rituximab, idasanutlin, or venetoclax formulation
History of hypersensitivity reactions to study drug or any component of the study drug formulation
Known hypersensitivity to any study drug component
Known hypersensitivity to any component of required drugs in the study
Participation in the DES component of the study.
Known allergy or reaction to any component of either study drug formulation
Known allergy or hypersensitivity to any component of the atezolizumab formulation
The tumor must not have an infratentorial component;
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Known allergy or reaction to any component of either study drug formulation
Known hypersensitivity to any component of study drug including potential subjects with a history of major immunologic reaction to any IgG-containing agent
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known allergy or reaction to any component of either study drug formulation
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
An allergy to a component of Levulan
have a known or suspected allergy to the study drug or any study drug component;
Known hypersensitivity or allergy to any component of the avelumab formulation
Known hypersensitivity to any component of the investigational products
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to an component of bevacizumab
Known allergy or hypersensitivity to any component of the investigational drug product.
Known hypersensitivity to any component of the nivolumab or ipilimumab product
Known hypersensitivity to immunoglobulins or any other component of the study drug
Known hypersensitivity to any component of the investigational product
Known hypersensitivity to 5-fluorouracil, capecitabine, bevacizumab or to any component of the investigational products or compounds of similar chemical composition
Known hypersensitivity to any study drug component.
Known hypersensitivity to any component of the product (lenvatinib or ingredients).
Serum M component (? 0.5 g/dL), or
History of hypersensitivity to any component of the formulation
History of hypersensitivity to active or inactive excipients of any component of treatment
Known allergy or reaction to any component of the MEDI4736 formulation or its excipients
Known hypersensitivity to any component of bevacizumab
Known contraindication or hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of Avastin
Patient with documented hypersensitivity to any of the component medications
History of hypersensitivity to any component of the formulation
History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
History of hypersensitivity to any component of the formulation
Known hypersensitivity to any component of topotecan or doxorubicin or other required drugs in the study
Known hypersensitivity to any component of the study medication(s).
Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.
Known prior severe hypersensitivity to investigational products or any component in their formulations
Participant has hypersensitivity to any component of TMZ or dacarbazine.
Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).
Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material
DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
Known prior or suspected hypersensitivity to study drugs or any component in their formulations
Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL-2 or any component of the formulation
History of allergy or hypersensitivity to any component of the treatment
Hypersensitive or intolerant to any component of the study drug(s) formulation
Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component
Patients with a history of hypersensitivity to sirolimus or any component of the formulation.
Known hypersensitivity to any study drug component
Patients must not have any known allergy or reaction to any component of the MEDI4736 formulation
Known allergy or hypersensitivity to any component of the atezolizumab formulation
Known allergy or hypersensitivity to any component of the bevacizumab formulation
Known hypersensitivity to any component of lenvatinib or midazolam.
Known hypersensitivity to a component of protocol therapy
Known hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study products
Known hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycol
History of hypersensitivity to any component of the formulation.
Patients with a known hypersensitivity to any component of bevacizumab are not eligible for this trial
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation
Extensive intraductal component
Known immediate or delayed hypersensitivity reaction to carboplatin, paclitaxel, polysorbate 80, or any other component of the formulation
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to 5-fluorouracil or to any component of the investigational products or compounds of similar chemical composition
Has a known hypersensitivity, intolerability or contraindication to any component of study treatment, including premedication
Participants who have known hypersensitivity to any component of loperamide or budesonide
Patients with a known hypersensitivity to any component of bevacizumab are not eligible for participation
History of allergy or hypersensitivity to any component of the study drugs
Known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of bevacizumab
Subjects with less than 25% intraductal component
Known hypersensitivity to any component of the trial agents
Known hypersensitivity to any component of the formulation
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide long-acting release [LAR] formulations
History of hypersensitivity to any component of the formulation
Known hypersensitivity to any component of bevacizumab
CARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulation
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of bevacizumab and osimertinib
Patients with known hypersensitivity to any component of bevacizumab
History of allergy or reaction to any component of the MEDI-551 formulation
History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI; hypersensitivity skin test is required at screening to rule out allergy to S. cerevisiae
Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.
Known hypersensitivity to any component of recombinant protein production by CHO cells
Known allergy or hypersensitivity to any component of the study treatment(s)
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Hypersensitivity to PEG or other component of AEB1102 (Co-ArgI-PEG)
Known hypersensitivity to any component of atezolizumab formulation or other study medication
Known hypersensitivity to any component of study treatments
Known hypersensitivity to any component of study treatments
Known hypersensitivity to bevacizumab or any component of its formulation
Subject has a known history of serious hypersensitivity to ASP2215, or any component of the formulation used.
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Known hypersensitivity to any component of study treatments
Previous known sensitivity to any Fibrin Sealant Grifols component or any Surgicel® component.
Known allergy or hypersensitivity to any component of the formulation of CA-4948 used in this study
Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-207, or known allergy to both penicillin and sulfa
Subjects who are known or suspected to be hypersensitive to any component of the study medications.
Allergic to diphtheria toxin a component of the study drug A-dmDT390-bisFv(UCHT1).
Subject has known history of serious hypersensitivity reaction to ASP8273, or any component of the formulation used.
Known hypersensitivity to any component of RDHAP
Known hypersensitivity to somatostatin analogs or any component of the pasireotide long acting release (LAR) or suspension concentrate (s.c.) formulations
Known hypersensitivity to any component of the atezolizumab product
Known hypersensitivity reaction to any component of ferric carboxymaltose
Patients with known hypersensitivity to NT-I7 or any component used in the vehicle/formulation are ineligible
Known hypersensitivity to any component of bevacizumab
Known hypersensitivity to any component of testosterone
Hypersensitivity/allergy or contraindication to any component of the stent, delivery system, or medication required to complete the procedure,which in the investigator's opinion cannot be adequately premedicated
Educational component: men over the age of 18
Screening component: men over age 40
Documented hypersensitivity to any component of ranolazine (Ranexa) pills
History of hypersensitivity or allergic reaction to NRT, or any component of its formulation
Any known allergy or hypersensitivity to vaginal lubricants or any component of study product
Known hypersensitivity to any component of the nivolumab or ipilimumab product
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
History of allergy or hypersensitivity to any component of the treatment
Patients with known hypersensitivity or allergy to any component of Sonazoid.
Patients with known hypersensitivity or allergy to any component of Definity
Hypersensitivity to NVB or any of its excipients or to any component of AVD + BV therapy
Patients with known hypersensitivity to any component of Definity micro bubble contrast
Known hypersensitivity to gemcitabine or any component of the formulation.